A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03099135
- Locations
- π΅π±
Hepid Diagnostyka I Terapia Tomasiewicz Kiciak Lekarze Spolka Partnerska, Lublin, Poland
π¨π¦LAIR Centre, Vancouver, British Columbia, Canada
π¨π¦Vancouver Prostate Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Phase 3
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 230
- Registration Number
- NCT03097133
- Locations
- πΉπ·
Bursa Sevket Yilmaz Research and Training Hospital, Bursa, Turkey
πͺπΈClinica Univ. de Navarra, Pamplona, Spain
πΉπ·Uludag University Medical Faculty, Bursa, Turkey
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1048
- Registration Number
- NCT03090100
- Locations
- π¨πΏ
Dermatologicka ambulance, Svitavy, Czechia
πΊπΈIndiana Clinical Trial Center, Plainfield, Indiana, United States
πΊπΈCentral Dermatology, Saint Louis, Missouri, United States
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT03089918
- Locations
- π§πͺ
UZ Leuven, Leuven, Belgium
π§πͺUniversity of Antwerpen, Wilrijk, Belgium
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64179375 0.3 mg/kgDrug: JNJ-64179375 2.5 mg/kgDrug: JNJ-64179375 1.0 mg/kgOther: PlaceboDrug: JNJ-64179375 (Dose to be Determined)
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT03080987
- Locations
- π¬π§
Hammersmith Medicines Research Ltd, London, United Kingdom
π―π΅Souseikai Hakata Clinic, Fukuoka, Japan
A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03066687
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT03059303
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03058419
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Pharmacokinetic Study of MABp1 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: MABp1
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT03047317
- Locations
- πΊπΈ
XBiotech Investigative Site, Austin, Texas, United States
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Phase 3
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 226
- Registration Number
- NCT03039192
- Locations
- πΊπΈ
Rush University, Chicago, Illinois, United States
πͺπͺNorth Estonian Medical Centre Foundation, Tallinn, Estonia
πͺπͺTartu University Hospital, Tartu, Estonia
Β© Copyright 2025. All Rights Reserved by MedPath